A data analytics study by nference, published September 15, 2026, and reported October 3, has provided the first large-scale quantification of real-world BPC-157 adoption in the United States. Researchers analyzed more than 15 million medical records and identified 1,039 patients whose physicians manually documented BPC-157 use in written clinical notes.
The study found that the number of new confirmed BPC-157 users increased 33-fold between 2020 and 2026. The peptide, which lacks FDA approval, has been promoted by Health and Human Services Secretary Robert F. Kennedy Jr. and is often marketed as the “Wolverine stack” when combined with TB-500. It is being used for a wide range of conditions including pain, tissue healing, and performance enhancement.
The findings come at a time of heightened regulatory attention to unapproved peptides. In July 2026, an FDA advisory panel voted to recommend BPC-157 for inclusion on the 503A Bulk Drugs List, a decision the FDA has not yet acted upon.
What happened
nference, a data analytics company, conducted a retrospective analysis of over 15 million medical records to identify documented instances of BPC-157 use. Researchers found 1,039 patients whose doctors had manually noted BPC-157 use in clinical notes — a method that only captures patients whose use was explicitly documented by a physician, which may limit the completeness of the count.
Among the 1,039 identified patients, reasons for use were documented in 644 cases. There was no placebo or control group, and only about one-third of patients had treatment responses recorded. The study did not provide controlled clinical evidence of safety or effectiveness.
The peptide is frequently discussed on social media and telehealth platforms, often in combination with TB-500 under the colloquial name “Wolverine stack.” Despite its growing popularity, BPC-157 is not FDA-approved and has limited human safety and effectiveness data available.
Why it matters
This study represents the first systematic effort to quantify real-world BPC-157 adoption in the United States. The 33-fold increase in new users between 2020 and 2026 underscores how rapidly unapproved peptides can spread through consumer demand, telehealth prescribing, and compounding pharmacy supply chains — even in the absence of robust human safety data.
The findings are relevant to multiple stakeholders. For regulators, the data provides a concrete measure of the scale of unapproved peptide use that the FDA must consider as it weighs whether to add BPC-157 to the 503A Bulk Drugs List. For clinicians, the study highlights the need for better documentation and patient counseling around substances patients may be using without established clinical evidence. For telehealth operators and compounding pharmacies, the data signals a growing market that carries both opportunity and regulatory risk.
The involvement of HHS Secretary Kennedy, who has publicly backed BPC-157, adds a political dimension to what is otherwise a scientific and regulatory question about unapproved substances.
What to watch next
- Whether the FDA acts on the July 2026 advisory panel recommendation to include BPC-157 on the 503A Bulk Drugs List, which would affect compounding pharmacy rules.
- Whether additional real-world evidence studies emerge to better characterize BPC-157 safety and effectiveness — or whether formal clinical trials are initiated.
- How telehealth platforms and compounding pharmacies respond to growing scrutiny of unapproved peptide prescribing.
Sources
Industry information only. Not medical or legal advice.
